Follow Us
© 2026 Arizent. All rights reserved.
CVS Health’s drug benefits unit is trying to entice health insurance plans to cover Wegovy, Novo Nordisk’s pricey weight-loss shot, for more patients by allowing them to charge copays as high as $200.
It’s the latest move by pharmacy benefit managers, which negotiate drug prices on behalf of health plans, to deal with the surging demand for weight-loss medicines. The copay option would take effect starting next year.
For reprint and licensing requests for this article, click here.
As more Americans turn to GLP-1 medications for weight loss, employers are weighing the benefits of coverage against rising healthcare expenses and long-term costs.
A look at what the Medicare GLP-1 Bridge Program covers, what it doesn't, and what plan sponsors need to know.
A growing share of employers are rethinking coverage of the weight-loss drugs as costs rise and early expectations of lower obesity rates and surgical needs have yet to surface in claims data.
Only 4.4% of newly-eligible patients would be covered by the projected $900 million in savings, according to new research.
Novo Nordisk will cut prices for Ozempic and Wegovy by up to 50% next year, prompting employers to plan for rising use and manage benefits costs.
